150 related articles for article (PubMed ID: 35506102)
1. Real-world dosing characteristics and utilization of parenteral treprostinil in the outpatient setting.
Balasubramanian VP; Safdar Z; Sketch MR; Broderick M; Nelsen AC; Lee D; Melendres-Groves L
Pulm Circ; 2022 Jan; 12(1):e12016. PubMed ID: 35506102
[TBL] [Abstract][Full Text] [Related]
2. Implementing the EXPEDITE parenteral induction protocol: Rapid parenteral treprostinil titration and transition to oral treprostinil.
Kingrey JF; Miller CE; Franco V; Smith JS; Zolty R; Oudiz RJ; Elwing JM; Huston JH; Melendres-Groves L; Ravichandran A; Balasubramanian V; Wu B; Hwang S; Seaman S; Broderick M; Rahaghi FF
Pulm Circ; 2023 Jul; 13(3):e12255. PubMed ID: 37497167
[TBL] [Abstract][Full Text] [Related]
3. Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension.
Raina A; Coons JC; Kanwar M; Murali S; Sokos G; Benza RL
Pulm Circ; 2013 Jan; 3(1):116-20. PubMed ID: 23662183
[TBL] [Abstract][Full Text] [Related]
4. Rapid Inpatient Titration of Intravenous Treprostinil for Pulmonary Arterial Hypertension: Safe and Tolerable.
El-Kersh K; Ruf KM; Smith JS
Am J Ther; 2018; 25(2):e213-e217. PubMed ID: 27003321
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis.
Song C; Kunovszki P; Beaudet A
J Health Econ Outcomes Res; 2022; 9(1):151-160. PubMed ID: 35800882
[No Abstract] [Full Text] [Related]
6. Subcutaneous to intravenous prostacyclin analog transition in pulmonary hypertension.
Alkukhun L; Bair ND; Dweik RA; Tonelli AR
J Cardiovasc Pharmacol; 2014 Jan; 63(1):4-8. PubMed ID: 24084219
[TBL] [Abstract][Full Text] [Related]
7. Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series.
Fanous SM; Janmohamed M
Am J Health Syst Pharm; 2018 Dec; 75(23):1877-1881. PubMed ID: 30301721
[TBL] [Abstract][Full Text] [Related]
8. Titration of pulmonary arterial hypertension therapeutics: Experience-based recommendations.
Lombardi S; Kingman M; Duncan M; Berngard SC; Fernandes T
Respir Med; 2018 Oct; 143():139-146. PubMed ID: 30261985
[TBL] [Abstract][Full Text] [Related]
9. Transition from IV epoprostenol to oral treprostinil in a patient with group 1 pulmonary arterial hypertension.
Sarangarm P; Elwood K
Am J Health Syst Pharm; 2021 Nov; 78(23):2110-2115. PubMed ID: 34100906
[TBL] [Abstract][Full Text] [Related]
10. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series.
Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C
J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480
[TBL] [Abstract][Full Text] [Related]
11. Transitioning From Intravenous to Subcutaneous Prostacyclin Therapy in Neonates With Severe Pulmonary Hypertension.
Turbenson MN; Radosevich JJ; Manuel V; Feldman J
J Pediatr Pharmacol Ther; 2020; 25(7):647-653. PubMed ID: 33041721
[TBL] [Abstract][Full Text] [Related]
12. Transitioning Parenteral or Inhaled Treprostinil to Oral Treprostinil Diolamine: Case Series and Review of the Literature.
Smith ZR; Kelly B; Awdish RL; Hegab S
J Pharm Pract; 2019 Oct; 32(5):599-604. PubMed ID: 29558853
[TBL] [Abstract][Full Text] [Related]
13. Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension.
Radosevich JJ; DeChristopher A; Irandost M; Fann J; Feldman J
Am J Health Syst Pharm; 2020 Jul; 77(15):1208-1212. PubMed ID: 32620953
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations.
Mathier MA; McDevitt S; Saggar R
J Heart Lung Transplant; 2010 Nov; 29(11):1210-7. PubMed ID: 20855220
[TBL] [Abstract][Full Text] [Related]
15. Transition protocol from subcutaneous treprostinil to intravenous epoprostenol in deteriorating patients with pulmonary arterial hypertension.
Mouratoglou SA; Patsiala A; Feloukidis C; Karvounis H; Giannakoulas G
Int J Cardiol; 2020 May; 306():187-189. PubMed ID: 32115272
[TBL] [Abstract][Full Text] [Related]
16. Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension.
Pugliese SC; Bull TM
Integr Blood Press Control; 2016; 9():1-7. PubMed ID: 26869810
[TBL] [Abstract][Full Text] [Related]
17. Transition From Subcutaneous or Inhaled Treprostinil to Oral Treprostinil at Home in Patients With Pulmonary Arterial Hypertension: A Retrospective Case Series.
Ackerbauer KA; Tandon R
J Pharm Pract; 2018 Apr; 31(2):163-166. PubMed ID: 28464760
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous and Intravenous Treprostinil Pharmacokinetics in Children With Pulmonary Vascular Disease.
Hall K; Ogawa M; Sakarovitch C; Hopper RK; Adamson GT; Hanna B; Ivy DD; Miller-Reed K; Yung D; McCarthy E; Siehr-Handler SL; Feinstein JA
J Cardiovasc Pharmacol; 2019 Jun; 73(6):383-393. PubMed ID: 31162247
[TBL] [Abstract][Full Text] [Related]
19. Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine.
Douwes JM; Zijlstra WMH; Rosenzweig EB; Ploegstra MJ; Krishnan US; Haarman MG; Roofthooft MTR; Postmus D; Hillege HL; Ivy DD; Berger RMF
Ann Am Thorac Soc; 2022 Feb; 19(2):227-237. PubMed ID: 34181866
[No Abstract] [Full Text] [Related]
20. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.
Oudiz RJ; Schilz RJ; Barst RJ; Galié N; Rich S; Rubin LJ; Simonneau G;
Chest; 2004 Aug; 126(2):420-7. PubMed ID: 15302727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
